STOCK TITAN
  1. Home
  2. News
  3. CDTX

Cidara Therapeutics Inc - CDTX STOCK NEWS

Welcome to our dedicated news page for Cidara Therapeutics (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cidara Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cidara Therapeutics's position in the market.

News
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
Rhea-AI Summary
Cidara Therapeutics announces new preclinical data on its drug-Fc conjugate candidate, CBO421, which shows potential for inhibiting tumor growth in solid tumors. The CD73-targeting DFC combines small molecule inhibitors and monoclonal antibodies against CD73, demonstrating best-in-class activity to inhibit immune evasion by cancer cells. The company plans to advance this candidate into clinical trials for the treatment of solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
clinical trial
-
News
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Cidara Therapeutics, Inc. reported financial results for Q3 2023, including revenue of $12.7 million and $46.3 million for the three and nine months ended September 30, 2023, respectively. The company received positive CHMP opinion for rezafungin, and Melinta received a product-specific J-Code and NTAP for REZZAYO. Janssen Pharmaceuticals delivered an Election to Proceed Notice for CD388, and Cidara received a $7.0 million milestone payment. Cash and cash equivalents totaled $48.7 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
earnings
-
News
Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults¹
Rhea-AI Summary
Mundipharma and Cidara Therapeutics announced positive opinion for rezafungin as a treatment for invasive candidiasis in adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
Rhea-AI Summary
Cidara Therapeutics announces new data on its drug-Fc conjugate (DFC) candidate, CD388, at IDWeek 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
clinical trial
-
News
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Cidara Therapeutics grants 330,000 shares of common stock to new employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
Rhea-AI Summary
Cidara Therapeutics will present new data on its drug-Fc conjugate candidate, CD388, at IDWeek 2023. CD388 is being developed for universal protection against influenza A and B. Janssen Pharmaceuticals intends to transfer its rights and obligations for CD388 to another entity. Cidara also received FDA approval for REZZAYO™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences
News
Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023
Rhea-AI Summary
Cidara Therapeutics to host virtual R&D Day, providing updates on Phase 2a data for JNJ-0953 drug candidate for universal prevention of seasonal influenza and insights into oncology DFCs targeting solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
-
News
Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference
Rhea-AI Summary
Cidara Therapeutics to present at H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
-
News
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
Rhea-AI Summary
Janssen Pharmaceuticals has elected to proceed with CD388, an influenza prevention drug being developed by Cidara Therapeutics. Cidara will receive a $7 million milestone payment and could potentially earn $685 million in milestones and royalties. CD388 has shown promising interim efficacy and safety data in Phase 1 and 2a trials, with a single dose decreasing viral replication and lowering influenza incidence rate compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.1%
Tags
none
News
Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development
Rhea-AI Summary
Cidara Therapeutics appoints Dr. Nicole Davarpanah as Senior VP of Translational Research & Development. She will lead the company's oncology efforts and focus on the strategy for developing drug candidates. Dr. Davarpanah brings expertise in immuno-oncology drug development and corporate development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
management
Stock CDTX logo
Cidara Therapeutics Inc

Nasdaq:CDTX

CDTX Rankings

#4574 Ranked by Market Cap
#734 Ranked by Stock Gains
N/A Ranked by Dividends

CDTX Stock Data

73.40M
76.81M
7.53%
30.63%
0.22%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About CDTX

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.